Tr1x
San Diego
About Tr1x
Tr1X is a biotechnology company that specializes in the development of allogeneic engineered regulatory T (Treg) and chimeric antigen receptor Treg (CAR-Treg) cell therapies aimed at treating autoimmune and inflammatory diseases. Tr1X's lead investigational therapy, TRX103, is an allogeneic engineered T cell product derived from CD4+ cells sourced from healthy donors, designed to mimic the function of Type 1 regulatory T (Tr1) cells. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TRX103, allowing the initiation of clinical trials for treatment-refractory Crohn’s Disease. Additionally, Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the TRX103 Phase 1/2a clinical trial for Graft-Versus-Host Disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $133.0M
- Last round: Series Unknown (Oct 2025)
- Website: tr1x.bio
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/tr1x-124751 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.